Lamassu Biotech Reports Early Safety Data for SA53
Madrid, Spain, U.S., October 26, 2026 Lamassu Biotech has presented initial safety and pharmacokinetic findings from the ongoing first-in-human...
Phase 2a
Advertisement
Immuneering Presents Atebimetinib Pancreatic Cancer Data at AACR
NEW YORK — September 28, 2026 Immuneering Corporation presented new data at the 2026 AACR Conference on Pancreatic Cancer...
CervoMed Advances Neflamapimod With New Tablet and FDA Dose Flexibility
BOSTON — September 28, 2026 CervoMed Inc. announced pharmacokinetic, regulatory and manufacturing advances for neflamapimod, including a new 50...
Eton Launches U.S. Commercial Availability of IMPAVIDO
DEER PARK, Ill. — September 28, 2026 Eton Pharmaceuticals, Inc. announced the U.S. commercial launch of IMPAVIDO® (miltefosine) capsules,...
Tiziana Doses First Participants in ALS Foralumab Trial
BOSTON, Mass. — September 28, 2026 Tiziana Life Sciences, Ltd. announced that the first three participants have been dosed...
Advertisements
Persevere Therapeutics Doses First Patient in MIROC-1
CHESTERBROOK, Pa. — September 24, 2026 Persevere Therapeutics, Inc. announced that the first patient has been enrolled and treated...
Evommune to Present EVO301 Phase 2a Data at EADV 2026
PALO ALTO, Calif. and NEW YORK — September 23, 2026 Evommune, Inc. announced that Phase 2a data for EVO301...
Oruka Reports Positive Week 28 ORKA-001 Psoriasis Data
MENLO PARK, Calif. — September 23, 2026 Oruka Therapeutics announced positive Week 28 data from the ongoing EVERLAST-A Phase...
Wave Initiates Phase 2a WVE-007 Combination Trial for Obesity
CAMBRIDGE, Mass. — September 23, 2026 Wave Life Sciences announced the initiation of a Phase 2a clinical trial evaluating...
Filana Gains FDA Lift of Simufilam Clinical Hold
AUSTIN, Texas — September 22, 2026 Filana Therapeutics announced that the U.S. Food and Drug Administration has lifted the...
Advertisement
